Search Results
You are looking at 1 - 4 of 4 items for
- Author: T Tsuji x
- Refine by access: All content x
Search for other papers by N Hirayama in
Google Scholar
PubMed
Search for other papers by K Kitamura in
Google Scholar
PubMed
Search for other papers by T Imamura in
Google Scholar
PubMed
Search for other papers by J Kato in
Google Scholar
PubMed
Search for other papers by Y Koiwaya in
Google Scholar
PubMed
Search for other papers by T Tsuji in
Google Scholar
PubMed
Search for other papers by K Kangawa in
Google Scholar
PubMed
Search for other papers by T Eto in
Google Scholar
PubMed
In the biosynthesis of adrenomedullin (AM), an intermediate form, AM(1-52)-glycine-COOH (iAM), is cleaved from proAM and subsequently processed to a biologically active mature form, AM(1-52)-NH2 (mAM), by enzymatic amidation. We recently reported that immunoreactive AM in human plasma consists of mAM and iAM. To clarify the pathophysiological roles of mAM and iAM in heart failure, we established an assay method to specifically detect mAM, and we determined the plasma concentrations of mAM and iAM in 68 patients with congestive heart failure (CHF). The plasma mAM concentrations of the CHF patients classified as being class I or II of New York Heart Association (NYHA) functional classification were significantly greater than those of the 28 healthy controls, and a further increase was noted in the class III or IV patients. Similar increases in plasma iAM were also observed in these patients compared with controls. The increased plasma mAM and iAM in 12 patients with exacerbated CHF were significantly reduced by treatment of their CHF for 7 days. In addition, the plasma concentrations of both mAM and iAM were significantly correlated with pulmonary capillary wedge pressure, pulmonary artery pressure, right atrial pressure, cardiothoracic ratio, heart rate, and the plasma concentrations of atrial and brain natriuretic peptides in the CHF patients. Thus the plasma concentrations of both mAM and iAM were increased progressively in proportion to the severity of CHF. These results suggest that, though the role of iAM remains to be clarified, mAM acts against the further deterioration of heart failure in patients with CHF.
Search for other papers by K Kashimada in
Google Scholar
PubMed
Search for other papers by T Yamashita in
Google Scholar
PubMed
Search for other papers by K Tsuji in
Google Scholar
PubMed
Search for other papers by A Nifuji in
Google Scholar
PubMed
Search for other papers by S Mizutani in
Google Scholar
PubMed
Search for other papers by Y Nabeshima in
Google Scholar
PubMed
Search for other papers by M Noda in
Google Scholar
PubMed
Klotho mutant (kl/kl) mice exhibit growth retardation after weaning, and previous electron microscopic examination of GH-producing cells in pituitary glands revealed a reduction in GH granules. However, it has not been known whether growth retardation in klotho mutant mice is related to the loss of GH function. We therefore examined whether treatment with GH could rescue the retardation of growth. At the end of 3 weeks of treatment with human GH, the body weight of wild-type (WT) mice was increased. In contrast, body weight was not increased in klotho mutant mice even after the treatment with human GH. Another feature of klotho mutant mice is the presence of osteopetrosis in the epiphyses of long bones and vertebrae. Treatment with human GH increased trabecular bone volume in the epiphyseal region of WT tibiae. Interestingly, increase in trabecular bone volume by GH treatment was also observed in klotho mutant mice and, therefore, the phenotype of high bone volume in the klotho mice was further enhanced. These findings indicate that a GH receptor system in cancellous bones could operate in mutant mice. Thus, growth retardation in the klotho mutant mice is resistant against GH treatment even when these mice respond to GH treatment in terms of cancellous bone volume.
Search for other papers by M Takamoto in
Google Scholar
PubMed
Search for other papers by K Tsuji in
Google Scholar
PubMed
Search for other papers by T Yamashita in
Google Scholar
PubMed
Search for other papers by H Sasaki in
Google Scholar
PubMed
Search for other papers by T Yano in
Google Scholar
PubMed
Search for other papers by Y Taketani in
Google Scholar
PubMed
Search for other papers by T Komori in
Google Scholar
PubMed
Search for other papers by A Nifuji in
Google Scholar
PubMed
Search for other papers by M Noda in
Google Scholar
PubMed
Hedgehog signaling is considered to play a crucial role in chondrogenesis by regulation through a network of cytokine actions, which is not fully understood. We examined the effect of hedgehog signaling on the expression of core-binding factor a1 (Cbfa1), a critical transcription factor for the development of bone and cartilage. Primary chondrocytes prepared from the costal cartilage of newborn mice were treated with N-terminal fragment of recombinant murine sonic hedgehog (rmShh-N). Northern blot analysis indicated that Cbfa1 mRNA expression levels in the chondrocyte cultures were elevated by the treatment with rmShh-N. rmShh-N treatment enhanced 1.8 kb Cbfa1 promoter activity in chondrocytes, suggesting the presence of transcriptional control. As Cbfa1-binding site(s) have been located in the promoter of the receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) gene, we also examined RANKL expression. rmShh-N treatment upregulated RANKL and RANK mRNA expression levels in chondrocytes. Interestingly, RANKL suppressed the hedgehog enhancement of alkaline phosphatase activity in chondrocytes, suggesting the presence of a link between these signaling molecules. We conclude that hedgehog signaling activates Cbfa1 gene expression through its promoter in chondrocytes, and also activates and interacts with RANKL to maintain cartilage development.
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Muneaki Ishijima in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Kunikazu Tsuji in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Susan R Rittling in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Teruhito Yamashita in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Hisashi Kurosawa in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by David T Denhardt in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Akira Nifuji in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Yoichi Ezura in
Google Scholar
PubMed
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854-8082, USA
Department of Orthopaedics, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Search for other papers by Masaki Noda in
Google Scholar
PubMed
Mechanical stress to bone plays a crucial role in the maintenance of bone homeostasis. It causes the deformation of bone matrix and generates strain force, which could initiate the mechano-transduction pathway. The presence of osteopontin (OPN), which is one of the abundant proteins in bone matrix, is required for the effects of mechanical stress on bone, as we have reported that OPN-null (OPN−/−) mice showed resistance to unloading-induced bone loss. However, cellular mechanisms underlying the phenomenon have not been completely elucidated. To obtain further insight into the role of OPN in mediating mechanical stress effect on bone, we examined in vitro mineralization and osteoclast-like cell formation in bone marrow cells obtained from hind limb bones of OPN−/− mice after tail suspension. The levels of mineralized nodule formation of bone marrow cells derived from the femora subjected to unloading were decreased compared with that from loaded control in wild-type mice. However, these were not decreased in cells from OPN−/− mice after tail suspension compared with that from loaded OPN−/− mice. Moreover, while spreading of osteoclast-like cells derived from bone marrow cells of the femora subjected to unloading was enhanced compared with that from loaded control in wild-type mice, this enhancement of spreading of these cells derived from the femora subjected to unloading was not recognized compared with those from loaded control in OPN−/− mice. These data provided cellular bases for the effect of the OPN deficiency on in vitro reduced mineralized nodule formation by osteoblasts and on enhancement of osteoclast spreading in vitro induced by the absence of mechanical stress. These in vitro results correlate well with the resistance to unloading-induced bone loss in OPN−/− mice in vivo, suggesting that OPN has an important role in the effects of unloading-induced alterations of differentiation of bone marrow into osteoblasts and osteoclasts.